Pulmatrix Stockholders Approve Eos SENOLYTIX Reverse Merger and Reverse Split
PULM sits 22% above its 52-week low of $1.16 on light trading volume (0.2× avg).
Summary
Pulmatrix stockholders approved all nine proposals at the October 26 special meeting, clearing the share issuance, reverse split and authorized-share increase required to close the Eos SENOLYTIX reverse merger.
Key Events · M&A and Partnerships · PULM
-
All Merger Proposals Approved
Stockholders approved all nine proposals at the October 26, 2026 special meeting, including the issuance of more than 20% of pre-deal shares to Eos stockholders, Eos noteholders and Palladium, and the resulting change of control under Nasdaq Rules 5635(a) and 5635(b).
-
Reverse Split and Share Increase Cleared
Proposal 2 authorizes a reverse split of one new share for every 2 to 10 outstanding shares at a ratio set by the board and agreed to by Eos; Proposal 3 raises authorized common stock from 200,000,000 to 250,000,000 shares.
-
Vote Tallies and Quorum
Proposal 1 drew 1,410,737 for, 172,166 against, 22,400 abstain and 916,593 broker non-votes; 61.40% of total voting power was represented, with 4,106,830 votes outstanding as of the August 28, 2026 record date.
-
Auditor and Board Items Passed
CBIZ CPAs P.C. was ratified for fiscal 2026, with Stephano Slack LLC expected to be appointed for the Combined Company if the merger closes; Michael J. Higgins and Anand Varadan were elected as Class III directors, serving only until the merger is completed.
Analysis · PULM · Life Sciences
Every proposal needed to close the Eos SENOLYTIX reverse merger passed, including the issuance of more than 20% of Pulmatrix's pre-deal shares to Eos holders and Palladium, a reverse split of 1-for-2 to 1-for-10, and an increase in authorized shares from 200 million to 250 million. For a company that reported a going concern warning with just $2.2 million of cash in its August 10-Q, this vote removes the biggest remaining hurdle to survival — the merger was the only clear path forward. What's left is satisfying the remaining closing conditions and Nasdaq listing of the Combined Company; the filing does not state a closing date.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PULM was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $1.16 to $4.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.